255 Zac1, jointly down-regulated by preconditioning and postconditioning in a mouse model of myocardial ischemia/reperfusion: a transcriptomic approach  by Gahide, Gérald et al.
© Elsevier Masson SAS. All rights reserved.
 
82 Archives of Cardiovascular Diseases Supplements (2010) 2, 80-86
Introduction: β-adrenergic system is altered in heart failure (HF) due to
non-ischemic dilated cardiomyopathy (DCM). There are few data concerning
the relative contribution of β1- and β3-adrenoceptor subtypes (β1- and β3-AR)
during DCM development. We evaluated the expression and the role of each
β-AR subtype in this pathology.
Methods: DCM rat model is performed by doxorubicin injections (cumu-
lative dose: 15 mg.kg-1) and validated by in vivo measurements with echocar-
diography-doppler. The variations of β1- and β3-AR transcript expression in
left ventricle (LV) are evaluated by real-time RT-PCR. The ex vivo cardiac
responses induced by selective β3-AR or non-selective β-AR stimulations are
evaluated on isolated perfused heart.
Results: DCM rats present LV dilation, systolic and diastolic dysfunction
(see table). Compared to controls, β1-AR transcripts and β3-AR transcripts are
increased in DCM LV (+36%, n=8, p<0.05 and +358 %, n=8, p<0.05). Ex vivo
parameters are summarized in the table.
Conclusion: DCM induces a β3-AR gene over-expression, associated to an
increase of β3AR-induced negative inotropic and lusitropic effects. Those
results could partly explain the alteration of isoproterenol response in our
model, suggesting that β3-AR could be a new therapeutic target in DCM.
253
Endothelial Estrogen Receptor α mediates the atheroprotective action
of 17β-Eestradiol in LDLr deficient mice
Audrey Billon, Coralie Fontaine, Pierre Gourdy, Jean Francois Arnal [Orateur] 
INSERM U858 – I2MR, Départ Biologie Vasculaire, Toulouse Cedex 4, France
Background: Although estrogen administration to hysterectomized meno-
pausal women did not prevent the occurence of myocardial infarction in a ran-
domized controlled trial (WHI 2004), epidemiological studies suggest and
experimental results clearly demonstrate a major atheroprotective action of
estrogens. The goal of the present study was to identify the cellular target(s)
accounting for the estradiol (E2) beneficial action on fatty streak development.
Methods and Results: We first confirmed the key role of estrogen receptor
α (ERα) in atheroprotective effect of E2 as this action was completely abolished
in mice deficient both in Low Density Lipoprotein receptor (LDLr) and in ERα.
Comparison of LDLr–/– mice transplanted with either ERα+/+ or ERα–/– bone
marrow showed that functional ERα in the hematopoietic lineage is not required
for E2 atheroprotection. We then showed that ERα floxed mice (ER_flox/flox)
bred with the Tie2-Cre mice on the LDLr–/–- background had a complete inac-
tivation of ERα both in bone marrow and in endothelial cells. Remarkably, in
this mouse model, the E2 atheroprotective action was completely abolished.
Conclusions: Altogether, this is the first in vivo demonstration that endot-
helial ERα represents a key target of the atheroprotective effect of E2, whereas
the hematopoietic ERα isdispensable for the protective action. Selective
estrogen receptor modulators that mimic this endothelial action of E2 should
now be considered in hormonal treatment as well as in atheroprotection.
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Objectives: Although reducing rates of restenosis, drug-eluting stents also
impair endothelial healing, resulting in increased risk of thrombosis. Alterna-
tively, inhibition of neointimal hyperplasia is favoured by acceleration of reen-
dothelialization. We previously showed that E2 accelerates reendothelialization
through Estrogen Receptor α (ERα) and we now aimed at defining the cellular
targets of this action.
Methods and Results: The respective roles of endothelial and hematopoi-
etic cellular targets of E2 were investigated in a mouse carotid injury model,
using “en face” confocal microscopy, to follow endothelium repair. Grafting
ERα –/– mice with ERα +/+ bone marrow (BM) did not restore the accelera-
tive effect of E2 on reendothelialization, demonstrating the necessary role of
extrahematopoietic ERα. Using a cell-specific inactivation of ERα (Cre-lox
recombination system), we showed that endothelial ER_ plays a pivotal role in
the E2 action. Finally, in wild type mice grafted with ERα –/–, the regenera-
tive effect of E2 was abolished, demonstrating that ERα-expressing hemato-
poietic cells are also concomitantly required.
Conclusions: We demonstrate that endothelial ERα plays a pivotal role in
E2-mediated reendothelialization. However, endothelial targeting alone is not
sufficient and the concomitant stimulation of BM ERα is absolutely required.
This cooperation should be now taken into account in strategies aimed at opti-
mizing in-stent reendothelialization.
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Ischemic preconditioning and postconditioning are two effective thera-
peutic strategies for reducing infarct size in animal models and humans. The
aim of our study was to compare the early regulated genes of preconditioning
and postconditioning using a transcriptomic approach.
Methods: C57Bl6, Zac1+/– KO (n=7) and WT littermates (n=4) mice
underwent an IR (40 min. ischemia/60 min.reperfusion) protocol. C57Bl6
mice were randomly assigned to different groups: IR (n=22); postconditioning
(PostC, n=21): a protocol of 3 cycles of 1-minute reperfusion and 1-minute
reocclusion was applied at the onset of reperfusion; preconditioning (PreC,
n=15; same algorithm but applied before ischemia. At the end of surgery, left
ventricles were assigned to RNA extraction or infarct size assessment. Home-
made mouse oligo microarrays were used for gene expression profiling (Mont-
pellier GenomiX Facilities). Determination of area at risk (AR) and infarct size
was assessed by TTC staining and planimetry.
Results: Our study revealed that despite a similar cardioprotection offered
by PreC and PostC on infarct size, PostC regulates a larger number of genes
compared to PreC (242 versus 40). Only 8 genes were jointly regulated by
PreC and PostC and considered as putative cardioprotective key regulators.
Among these candidates, Zac1 was down regulated at the transcriptional levels
upon PreC and PostC. Moreover, infarct size/AR was 29%-decreased in Zac1
+/– KO mice subjected to a surgical protocol of myocardial IR.
Table: Basal parameters and maximum values obtained by non-selective 
β1-AR stimulation (isoproterenol) or selective β3-AR stimulation 
(SR58611A). Results are expressed by mean ± SEM.*: p<0.001 vs Control, 
£: p<0.001 vs Basal.
   Control rats 
(n=9-31)
DCM rats 
(n=10-31)
Basal 
in vivo  
 LV end-diastolic diameter (mm)  8.82±0.33 7.61±0.17 * 
 LV ejection fraction (%)  83.0±1.9 71.2±2.8* 
 LV Isovolumic relaxation 
time (ms)  21.41±1.13 32.39±1.10* 
Basal ex vivo
 DP/dt max (mmHg.s-1)  2035±365  2669±504*
 DP/dt min (mmHg.s-1)  –1258±226  –1847±349*
Isoproterenol 
ex vivo (1 μM)
 DP/dt max (mmHg.s-1)  5263±1754 4373±1383*
 DP/dt min (mmHg.s-1)  –3815±1271 –3227±1020*
SR58611A 
ex vivo (1 μM) 
 DP/dt max (mmHg.s-1) 1722±497  1930±611£
 DP/dt min (mmHg.s-1)  –1027±297 –1138±360£
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Conclusion: Using pangenomic microarrays, we identified and compared
the gene profiles of preconditioning and postconditioning versus IR in the
mouse left ventricle in vivo. Among the genes jointly downregulated by pre-
conditioning and postconditioning, Zac1 was identified as a putative cardio-
protective key regulator. Indeed downregulation at the transcriptional and
protein levels of Zac1 leads to cardioprotection against IR.
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Background: We have shown that the Sonic Hedgehog (Shh) embryonic
signalling pathway can be reactivated in myocardial infarction (MI) in adults
inducing expression of pro-angiogenic factors. We hypothesized that com-
bining Shh gene therapy and endothelial BM-derived pro-angiogenic cell
mobilization by a CXCR4 antagonist, AMD3100 (AMD), could exert syner-
gistic effects and would be superior to either single strategy for the treatment
of MI.
Methods/results: In vivo, MI was induced in WT and GFP-bone marrow
(BM) transplanted mice randomly assigned in 4 treatment groups: control;
AMD (single dose, 5mg/kg s.c.); Shh (intramyocardial; 100μg Shh plasmid
DNA at time of MI surgery); AMD+Shh group. Left ventricular ejection frac-
tion (LVEF) was evaluated by echo up to 4 weeks post MI. AMD+Shh group
exhibited the best LV function . Furthermore, combination of AMD with sub-
therapeutic dose of Shh resulted in a significant improvement of cardiac func-
tion recovery compared to monotherapy, highlighting its synergistic effect
(P<0.05). Elastic staining and immunohistological analyses demonstrated
reduced infarct size and increased capillary density in the AMD+Shh group
(both P < 0.05). Combination therapy was also associated with significant
increase in number of GFP-BS lectin BM-derived cells incorporated into the
ischemic area (P<0.05). We then explored the certain potential mechanisms of
the favourable effects of combination therapy. MMP-9 mRNA expression was
increased in ischemic myocardium in the AMD+Shh (10-fold versus control).
The positive effect on EF of combined treatment was attenuated in MMP-9
KO mice, suggesting that MMP-9 might be a key modulator of the combina-
tion therapy.
Conclusion: Pharmacological enhancement of Shh gene therapy via BM-
cell mobilization by a CXCR4 antagonist is mediated via an MMP-9-depen-
dent pathway. The combination may offer advantages in safety and feasibility
by allowing lower dose gene transfer while improving outcome post-MI
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Background: Cellular cardiomyoplasty has been proposed as an attrac-
tive strategy to repair myocardial damage. One of the crucial point is the
optimal delivery strategy. In the present study, we examined the use of an
implantable porous scaffold for promoting bone marrow-derived mesen-
chymal stem cells (MSCs) survival and functions in a rat model of acute
myocardial infarction.
Methods and Results: Cardiac patch was based on biodegradable polysaccha-
rides porous scaffold. After ligation of the left anterior coronary artery, the fate of
1x106 GFP+ MSC administered either using cellularized scaffold implantation or
direct injection was examined at 1 and 2 months. The number of residual GFP+
cells in the sample studied was estimated on the basis of the fluorescence emitted
by a defined number of GFP+ cells used for calibration. Cellularized scaffold
allowed a more efficient delivery and the difference with direct injection was sig-
nificant at 2 months, with respectively 2100±1300×103 and 215±85x103 residual
GFP+ cells (p<0.03). Cardiac tissue levels of matrix metalloproteinase-2 and -9
mRNA were similar whatever the administration conditions but a slight increase
in the local production of vascular endothelial growth factor was observed at 2
months after patch implantation in comparison to direct injection (p<0.05). In ani-
mals having received MSC implemented on scaffold, clusters of GFP+ cells,
mainly phenotypically consistent with immature MSC cells, were detected in the
peri-infarct area. The increased survival using scaffold was not translated in an
improved myocardial remodelling and functions with no significant difference in
the LVEDD, LVESD, and FS between the 2 groups as in comparison with animals
implanted with non cellularized scaffold.
Conclusions: These findings demonstrate that the implantation of cellular-
ized grafts is safe and effective for delivering mesenchymal stem cells into
damaged myocardium, and results in a better cellular engraftment compared to
direct injection.
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We investigated whether postischemic cardiac remodeling (REM) is accel-
erated in diabetic rats with possible involvement of thyroid hormone (TH) sig-
naling in this response. Changes in TH signaling occur during REM after acute
myocardial infarction (MI) and contribute to cardiac dysfunction.
Diabetes was induced in Wistar rats by streptozotocin injection (35mg/Kg
i.p.). After 30 days diabetic rats (DM-AMI, n=9) were subjected to MI, while
control rats were either sham-operated (SHAM, n=10) or subjected to MI
(AMI(1), n=10). After 2 weeks, TRα1 and TRα1 expression and TH levels
were measured. Hypothyroid rats by propyl-thiouracil administration (0.05%)
in water for 3 weeks were subjected to MI (HYPO-AMI, n=6) while untreated
MI rats served as controls (AMI(2), n=6). LV dimensions (LVEDD and
LVEDS) and ejection fraction (EF%) were used to assess contractility and
REM 2 weeks after MI using echocardiography. Cardiac function was mark-
edly decreased in DM –AMI.
In AMI(1), TRα1 and TRβ1 protein expression were not changed signifi-
cantly as compared to SHAM while in DM-AMI, both TRα1 and TRβ1 were
decreased 1.7 and 1.9 fold respectively as compared to SHAM, p<0.05. T3 and
T4 levels were not different between groups. HYPO-AMI hearts, with scar areas
comparable to AMI(2) hearts [97(4.7) vs 105 (10.3), p>0.05], showed a similar
unfavorable functional response : EF% was found to be markedly reduced [24
(0.9) in HYPO-AMI vs 36.2 (1.0) in AMI(2), p<0.05], while LVEDS was 8.3
(0.2) for HYPO-AMI and 7.5(0.1) for AMI(2), p<0.05. LVEDD equally
increased in the 2 groups. Postischemic cardiac remodeling is accelerated both
in hypothyroid and diabetic hearts. Tissue hypothyroidism which occurs in DM
after myocardial infarction,may at least in part, account for this response.
 Scar (mm2) LVEDD (mm) LVEDS (mm) EF%
SHAM ----- 6.5 (0.1) 3.8 (0.2) 76 (2.6)
AMI(1) 79 (4.0) 7.7 (0.2)* 5.7 (0.2)* 52 (1.5)*
DM-AMI 83 (4.9) 8.5 (0.2)** 7.0 (0.3)** 39 (2.1)**
*p<0.05 vs SHAM, **p<0.05 vs SHAM and AMI(1)
